Memorial Sloan Kettering Cancer Center

Ibrutinib — a Bruton tyrosine kinase inhibitor that inhibits B cell-receptor signaling — has demonstrated long-term efficacy as treatment for many mature B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.

The FDA cleared an investigational new drug application for ATA2271, a chimeric antigen receptor T-cell therapy for the treatment of advanced mesothelioma, according to the agent’s manufacturer.

Transoral robotic surgery appeared associated with improved surgical and long-term survival outcomes compared with nonrobotic surgery for patients with early-stage oropharyngeal cancer, according to study results published in JAMA Oncology.

Fox Chase Cancer Center announced several faculty appointments.

Recent cytotoxic chemotherapy treatment did not appear associated with adverse COVID-19 outcomes for patients with cancer, according to results of a retrospective study published in Journal of Clinical Oncology.

An induction-concurrent chemotherapy sequence conferred a PFS benefit for patients with locoregionally advanced nasopharyngeal carcinoma treated with conventional fractionated radiotherapy, according to study results published in Cancer.

American Society for Radiation Oncology selected 19 members to receive ASTRO fellow designation.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

Radiotherapy in combination with chemotherapy significantly improved OS among chemotherapy-sensitive patients with metastatic nasopharyngeal carcinoma, according to results of a randomized phase 3 study published in JAMA Oncology.

Switching a B-cell lymphoma or leukemia treatment from CD20-directed immunotherapy to an alternative option may offer a successful alternative to desensitization protocols in instances of severe drug hypersensitivity.